Hans-peter Kempe

Ludwigshafen Am Rhein, RP, DE 
Ludwigshafen Am Rhein, RP, DE 

Overview

Hans-peter Kempe practices practicing medicine in Ludwigshafen Am Rhein, Germany.

Their clinical expertise encompasses Maturity Onset Diabetes of the Young, Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and Low Blood Sugar.

They are actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 5 clinical trials.

Locations

Ludwigshafen Am Rhein, RP, Germany
Other Locations
Berlin, BE 10117, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: July 08, 2026
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
Enrollment Status: Completed
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
Enrollment Status: Completed
Publish Date: January 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

10 Total Publications

Perceptions of Suboptimal Insulin Dosing from People with Diabetes and Healthcare Professionals in Germany.
Perceptions of Suboptimal Insulin Dosing from People with Diabetes and Healthcare Professionals in Germany.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: March 05, 2025

Frequently Asked Questions about Hans-peter Kempe

Is Hans-peter Kempe a top-rated expert for Maturity Onset Diabetes of the Young?

MediFind is an objective health platform that identifies experts based on real-world data. Hans-peter Kempe is classified as an Experienced expert for Maturity Onset Diabetes of the Young, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hans-peter Kempe participate in research or clinical trials?

Yes. Hans-peter Kempe has published 10 articles and abstracts on conditions like Maturity Onset Diabetes of the Young. You can view a list of Hans-peter Kempe's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kempe's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile